John Petrie

Reposting for anyone who missed the below - places still available - great speakers confirmed - Programme in link - should be a fun and informative day! @glasgowctu.bsky.social

Logo for the EASD 2025 Annual Meeting in Vienna. The design features a large red and blue Ferris wheel, referencing Vienna’s famous Riesenrad, with the text "EASD 2025 VIENNA" centred in bold red and blue lettering. A blue outline frames the text.

📚 Weekend reading recommendation:
Browse the #EASD2025 Final Programme - 300+ pages packed with exciting content, from basic to clinical #diabetes #research.

📖 Explore the programme: www.easd.org/uploads/EASD...

🎟️ Register now: www.easd.org/annual-meeti...

#AnnualMeeting #ScientificProgramme

Please join us soon in Glasgow for a 1-day course on “How to be a Great Chief Investigator” featuring trialists and CTU experts from around Scotland - supported by UKCRC - *Thursday 9th October* - open to all! @bleedingstroke.bsky.social @kerryhood.bsky.social @glasgowctu.bsky.social registration >

Metformin- Should I Stay or Should I Go — NephJC This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?

Hi! We will discuss your article tonight 9 pm EST (I know, difficult hour for your timezone) #NephJC

Here is our take on your article www.nephjc.com/news/metform...

Real-world tirzepatide use in #T2D in 🇺🇸

🔹 Initiation: 84% start at ≤5 mg, 69.6% ⤴️ dose within 6m

🔸 Dosing at 6m: 56.5% remain <10 mg

🔹 Persistence: 73.3% still on treatment at 6m

🔸 Discontinuation: 26.7% stopped, 29.1% restarted

👉 Persistence high, slower titration the norm

🔗 ggdocs.co/0z0q43

Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes This network meta-analysis assesses whether age or sex are associated with differences in the efficacy of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipe...

ja.ma/4jE7Axf

SGLT2is were more cardioprotective in older people (despite smaller reductions in HbA1c) and GLP-1 RAs were more cardioprotective in younger people @uofglasgow.bsky.social

From David McAllister of University of Glasgow School of Health and Wellbeing using individual patient data meta-analysis and meta-regression . . .

Olympic swimming champion Gary Hall Jr., a hero to the #type1diabetes community, has lost his home and medals in the California fires. Gut wrenching.

Optimising allocation ratios in platform trials: role of simulation at University of Glasgow on FindAPhD.com PhD Project - Optimising allocation ratios in platform trials: role of simulation at University of Glasgow, listed on FindAPhD.com

Closing date for this opportunity at the University of Glasgow is approaching fast - if you think you could be the right person, please get in touch!

www.findaphd.com/phds/project...

Steatotic liver disease - PubMed Steatotic liver disease is the overarching term for conditions characterised by abnormal lipid accumulation in the liver (liver or hepatic steatosis). Steatotic liver disease encompasses what was prev...

www.ncbi.nlm.nih.gov/pubmed/39488... Lancet review

Nice conceptual model of “how everything is related to everything else” by Sven Francque (UZA, Antwerp, Belgium) at the Joint EGIR-MASLD EASD Study Group Meeting (insulin resistance/ metabolic liver disease), Lille, France today in a lecture on new EASL-EASD-EASO guidelines for MASLD

Finally published today! My heart is in my throat, but I hope that some of you will read it and find it interesting.
And I’d be very grateful for any reviews (Goodreads, Amazon…)

ESO Paper of the Month The Paper of the Month initiative is brought to you by the Council of Fellows to highlight interesting and relevant papers

🏆Exciting news! ATTEST-2 has been selected as
ESOS Paper of the Month. The study explores tenecteplase vs alteplase in acute ischaemic stroke, offering promising insights for stroke treatment. Proud of our researchers!🧠 #StrokeResearch #ClinicalTrials Read Here ⬇️
eso-stroke.org/resources/pa...

BlueSky auto-captioned this as “A room with people sitting around tables having discussions” - which at one level is pretty much what happened today . . . but on another level we planned the next 5 years of UK Clinical Trials Units strategy!

A room with people sitting around tables having discussions.

Homeward bound from a fabulous Directors meeting for @ukctunetwork.bsky.social. Lots of discussions about sustainability, funding and policy. Loads to think about for our strategic priorities.

www.ajkd.org/article/S027...

Shared this on Twitter this morning - and joined BlueSky this afternoon. First post - nice collaboration on Scottish nationwide diabetes data with Samira Bell @ University of Dundee. Innovative methodology and challenges received wisdom on withdrawing metformin after acute illness.